Clinical Study
Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients
Table 2
Ischemic complications.
| | Patient | Age | Baseline mRS | CHA2DS2-VASc | HAS-BLED | Dabigatran dose | Concomitant antiaggregation therapy | Event | TE (months) | Discontinued yes/no |
| | #1 | 85 | 3 | 5 | 2 | 110 | No | CI | 1 | Yes | | #2 | 95 | 1 | 6 | 3 | 110 | No | TIA | 10 | No | | #3 | 79 | 1 | 6 | 3 | 110 | No | CI | 1 | No | | #4 | 83 | 1 | 7 | 3 | 110 | No | TIA | 1 | No | | #5 | 50 | 4 | 3 | 1 | 150 | No | TIA | 1 | No | | #6 | 83 | 2 | 6 | 2 | 110 | No | TIA | 1 | No | | #7 | 83 | 2 | 6 | 2 | 110 | No | CI* | 1 | No | | #8 | 78 | 0 | 6 | 2 | 110 | Yes | TIA | 4 | No | | #9 | 73 | 0 | 6 | 2 | 110 | No | TIA | 6 | No | | #10 | 85 | 3 | 9 | 4 | 110 | No | NSTE-ACS | 8 | No |
|
|
CI: cerebral infarct. *Treated with intravenous tPA. mRS: Modified Rankin Scale. TE: time to event. TIA: transient ischemic attack. NSTE-ACS: non-ST-segment elevation acute coronary syndrome.
|
